MedTrace Logo

Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy

NCT07227285 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-11-12

No results posted yet for this study

Summary

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

Conditions

  • Urinary Bladder, Overactive
  • Spinal Cord Injury

Interventions

OTHER

Urodynamics

standardized local evaluation of urodynamic parameters

DRUG

EG110A

Patients already treated with EG110A

OTHER

Patient-reported Outcome

assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms

Sponsors & Collaborators

  • EG 427

    lead INDUSTRY

Principal Investigators

  • Cornelia Haag-Molkenteller, MD · EG 427

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2031-04-30
Completion
2031-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227285 on ClinicalTrials.gov